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ABSTRACT
Purpose. We examined the pattern of single-nucleotide
polymorphisms (SNPs) of gemcitabine metabolism-re-
lated and target genes in breast cancer patients and eval-
uated their association with drug response or toxicity.
Patients and Methods. SNPs in deoxycytidine kinase
(dCK), deoxycytidine monophosphate deaminase
(DCTD), and ribonucleotide reductase M1 polypeptide
(RRM1) were analyzed with genomic DNA of 10 breast
cancer cell lines, 74 peripheral blood mononuclear cell
(PBMC) samples from advanced breast cancer patients
treated with gemcitabine, and 56 PBMC samples from
healthy volunteers.
Results. The incidences of SNPs of breast cancer pa-
tients were 1.4% in dCK (626 A>G), 10.8% in DCTD
(315 T>C), 40.5% in the first RRM1 (1082 C>A),
44.6% in the second RRM1 (2455 A>G), 44.6% in the
third RRM1 (2464 G>A), and 23% in two RRM1 sites
(2455 A>G and 2464 G>A) that were similar to those of
the normal control group. We found a double SNP of
RRM1 (2455 A>G and 2464 G>A) to be the novel hap-
lotype that was associated with a lower frequency of
chemotherapy-induced toxicity, such as neutropenia
(p< .01) and G-CSF requirement (p< .005).
Conclusion. RRM1 haplotype showed an association
with susceptibility to gemcitabine monotherapy in
breast cancer patients. The Oncologist 2007;12:622–630
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Gemcitabine (22-difluorodeoxycytidine [dFdC]) is a spe-
cific analogue of the native pyrimidine nucleotide deoxy-
cytidine. It is a novel anticancer agent that has significant
activity in carcinomas of the ovary, lung, pancreas, and
breast [1]. Gemcitabine has a complex metabolic pathway
for cytotoxicity [2, 3]. It is transported into the cell by nu-
cleoside transporters, phosphorylated by deoxycytidine ki-
nase (dCK) to its active monophosphate form [4], further
phosphorylated to the triphosphate form, and then incorpo-
rated into the DNA. Therefore, dCK plays a key role in the
activation of gemcitabine and its activity correlates with
drug sensitivity [5–9]. Gemcitabine is inactivated by de-
oxycytidine monophosphate deaminase (DCTD) into its
inactive form of difluorodeoxyuridine (dFdU). Ribonucle-
otide reductase (RR) is the rate-limiting step in DNA syn-
thesis. It is the only known enzyme that converts
ribonucleotides to deoxyribonucleoside for DNA polymer-
ization and repair [10]. RR is a holoenzyme consisting of
dimerized RR subunit 1 and 2 (RRM1, RRM2). RRM1 has
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been shown to function with the p53-regulated RRM2 ho-
mologue p53R2, which is important in DNA repair second-
ary to genotoxic stress [11]. In in vitro studies, increased
RRM1 expression and activity has been shown to be a
marker for gemcitabine resistance [12–14].
In gemcitabine metabolism, where 13 genes are in-
volved, the first step in phosphorylation is catalyzed by
dCK, which is the rate-limiting step for further phosphory-
lation to active metabolites, and thus is essential for the ac-
tivation of gemcitabine. Alternatively, gemcitabine is
inactivated by DCTD into its inactive form. RRM1 is the
rate-limiting step of DNA synthesis and is inhibited by
diphosphorylated gemcitabine (dFdCDP). dCK deficiency,
increased DCTD, and increased RR activity are the main
mechanisms of gemcitabine resistance. Therefore, we
chose these three rate-limiting steps in our study focusing
on the gemcitabine metabolic pathway (DCTD, dCK) or
target molecule of gemcitabine (RRM1) as an association
marker of clinical outcome (response, toxicity) of gemcit-
abine monotherapy.
For single-nucleotide polymorphism (SNP) site selec-
tion, we tried to select nonsynonymous SNPs in the func-
tional and conserved region of the genes among known
SNPs when we designed this study. Therefore, we tried to
choose SNPs in the conserved coding region without any
known function of the SNP. With these criteria, we chose
two cSNP sites from DCTD (site 255 and 351) and two
cSNP sites from dCK (site 626 and 753) with no known
function. Among nine SNP sites in RRM1, we finally chose
three nonsynonymous cSNP sites (1082, 2455, 2464) lo-
cated in the LD block and located in the protein domain and
conserved region of RRM1.
With the development of a rapid and practical method of
genetic polymorphism analysis, we detected polymor-
phisms of dCK, DCTD, and RRM1 in advanced breast can-
cer patients who received gemcitabine monotherapy. And
we performed an association study to test the relationship
between clinical phenotypes and those genetic polymor-
phisms.
PATIENTS AND METHODS
Patients and Healthy Volunteers
Seventy-four patients treated at Yonsei Cancer Center for
advanced breast cancer were enrolled in the study. Patients
eligible for this study had histologically confirmed breast
cancer with documented progression after prior use of an-
thracyclines and taxanes. All patients were required to
have a measurable lesion, to be 75 years of age or younger,
to have an Eastern Cooperative Oncology Group (ECOG)
performance status score of 2, to have an expected sur-
vival time of 12 weeks, and to have adequate bone mar-
row and renal and hepatic functions (hemoglobin 10.0
g/dl, leukocytes 3,000/mm3, platelets 100,000/mm3,
total bilirubin and serum creatinine 1.5 the upper nor-
mal limit and aspartate aminotransferase and alanine ami-
notransferase 2 the upper normal limit). Prior therapy
had to have been completed at least 4 weeks before study
entry with full resolution of toxicities. Informed consent
was obtained according to the institutional regulations. The
study protocol was approved by the institutional review
board. As a control, 56 healthy unrelated female blood do-
nors were included in the study. Patient characteristics are
summarized in Table 1.
Treatment Plan
Chemotherapy consisted of a single dose of gemcitabine,
850 mg/m2, on days 1, 8, and 15 every 28 days. There was
no modification of gemcitabine dose during the whole treat-
ment. If the patient had grade III leukopenia, the patient re-
ceived G-CSF support (150 g/m2) and the treatment was
delayed until recovery on a weekly base. No prophylactic
G-CSF was administered.






Total n of patients 74 56
Evaluated n of patients 71









Ductal carcinoma 72 (97.3)







Abbreviations: ER, estrogen receptor; PgR, progesterone
receptor.
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Assessment of Response and Toxicity
Antitumor activity was evaluated every three courses. Tu-
mor response was measured according to World Health Or-
ganization (WHO) criteria. In every course, toxicity was
evaluated by National Cancer Institute Common Toxicity
Criteria version 3.0.
Cell Lines and Cell Culture
Six human breast cancer cell lines (MCF/ADR, MDA-MB-
231, MDA-MB-435, MCF-7, T47D, and SK-BR-3) were
obtained from the American Type Culture Collection
(Rockville, MD). We also added another four cell lines
(YCC-B1, YCC-B2, YCC-B3, and YCC-B5) that had been
established from Korean breast cancer patients (Cancer
Metastasis Research Center, Seoul, Korea). The cells were
cultured and maintained in minimal essential medium sup-
plemented with 10% fetal bovine serum (GIBCO, Grand Is-
land, NY), 100 units/ml of penicillin, and 0.1 mg/ml of
streptomycin (GIBCO) in a humidified 37°C incubator with
5% CO2.
Drug Sensitivity Test by 3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetra Zoliumbromide (MTT)
Assay
Cells (1 104) were inoculated into each well of a 96-well
plate with various concentrations of gemcitabine. The
plates were incubated for 72 hours and then 5 g of MTT
was added to each well. After dissolving formazan, the
plates were read immediately at 570 nm using a model 550
Micro Plate Reader (Bio-Rad, Hercules, CA). The assays
were repeated three times.
Genomic DNA Extraction from Cell Lines and
Lymphocytes
The cultured cells were resuspended with DNA lysis buffer
(10 mM Tris-HCl [pH 7.6], 10 mM EDTA, 50 mM NaCl,
0.2% SDS, 20 mg/ml proteinase K) and incubated over-
night at 42°C. Using phenol:chloroform:isopropanol alco-
hol (GIBCO), we extracted genomic DNA and the pellet
was washed with 70% ethanol. The final concentration was
determined with Gene Quant RNA/DNA Calculator (Am-
ersham Pharmacia Biotech USA).
Peripheral blood lymphocytes were collected in hepa-
rinized vacutainer tubes (Becton Dickinson, Franklin
Lakes, NJ). Lymphocytes were isolated using Ficoll-Paque
(Pharmacia, Uppsala, Sweden) following the manufactur-
er’s instructions. Genomic DNA from lymphocytes was
isolated with the LaboPass™ Blood kit (Genotein Biotech,
Seoul, Korea). Extracted DNA was stored at70°C.
SNP Target Determinations
Target SNPs were determined using available SNP public
databases. The GeneCards (http://bioinformatics.weizmann.
ac.il/cards) and OMIM (http://www.ncbi.nlm.nih.Gov/
Omim) databases were used to gain information about the
genes in the gemcitabine metabolic pathway. Database que-
ries for SNPs in the gemcitabine metabolic pathway were
conducted in HOWDY (http://gdb.jst.go.jp/HOWDY/),
which includes dbSNP (http://www.ncbi.nlm.nih.gov/
SNP/) and JSNP (http://snp.ims.utokyo.ac.jp/) [2].
Polymerase Chain Reaction
The primer sequences used were as follows: DCTD exon
3 (forward, 5-CATCAGCAATGAGCTACTGA; re-
verse, 5-TGCAACC AAAGTTTTTCTTT), dCK exon 4
(forward, 5-CCACTGGATTTAGGAGAATG; reverse,
5-GTGAAACACATTTTTATTGGG), dCK exon 5
(forward, 5-AAAAGAAAATTTTGATG GCA; re-
verse, 5-ACTTCAGTGTCCTATGCAGG), RRM1 exon
9 (forward, 5-TTGATTTTAT TTGGGCATTT; re-
verse, 5-CAATTCAG GAGCATACCTT), and RRM1
exon 19 (forward, 5-TT CCTTGTAGGGTTTGAAGA;
reverse, 5-AGGATCCACACATCAGACAT). The con-
ditions of the polymerase chain reaction (PCR) amplifi-
cation were as follows: 95°C for 5 minutes followed by
94°C for 30 seconds, 57°C for 20 seconds, 72°C for 30
seconds, and 72°C for 2 minutes repeated for 30 cycles.
DNA Sequencing
Direct sequencing of each PCR product was carried out us-
ing CEQTM 8000 genetic analysis system (Beckman
Coulter, Inc., Fullerton, CA). The reaction mixture con-
tained 25–100 fmol of purified PCR products, 1.6 pmol/l
of either the sense or antisense oligonucleotides (same as
PCR primer) and DTCS premix (10 sequencing buffer,
dNTP mix, ddUTP/ddCTP/ddATP/ddGTP dye terminator,
polymerase enzyme). Each cycle of the sequencing reaction
consisted of 96°C for 20 seconds, 50°C for 20 seconds,
and 60°C for 4 minutes. The PCR products were dissolved
in Sample Loading Solution (CEQ Dye Terminator cycle
sequencing kit, Beckman Coulter, Inc.). After loading on
the CEQTM 8000 genetic analysis system, fluorescence
was detected. Sequence variances were checked by com-
paring them with reference sequences obtained from Gen-
Bank (DCTD, NM_001921.1; dCK, NM_000788; RRM1,
NM_001033.2).
Real-Time PCR Assay
RNA extraction was performed using TRIzol Reagent
(Invitrogen Corporation, Carlsbad, CA). The primer
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sequences used were as follows: RRM1 (forward,
5-ATCAGGACTGGTCTTTGATG-3; reverse, 5-TGA
GACTCAATGATGGCATA-3), -actin (forward, 5-
GGGAATTCAAAACTGGA ACGGTGAAG G-3; re-
verse, 5-GGAAGCTTATCAAAGTCCTCGGCCAC A-3).
PCR was performed at 95°C for 15 minutes in order to ac-
tivate the HotstarTaq DNA polymerase, and then for 35 cy-
cles of amplification at: 95°C for 20 seconds, 50°C for 30
seconds, and 72°C for 45 seconds. The amplified fluores-
cence signal in each specimen was measured at the last ex-
tension step of each cycle. In order to quantify each gene,
we used 10-fold serially diluted human genomic DNA
(Promega, Madison, WI). The standard curve was drawn by
plotting the measured threshold cycle versus the arbitrary
unit of the copies per reaction based on the serially diluted
genomic DNA of -actin. The threshold cycle (Ct) values
were determined as the cycle number at which the fluores-
cence exceeded the threshold value. In the negative control,
there was no fluorescent signal even after the cycle number
was increased more than 35-fold.
Western Blotting
Cells were resuspended in 50 l of lysis buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM CaCl2, 1 mM
MgCl2, and protease inhibitor mixture). The amount of
protein was quantitated using the Bradford Protein Assay
(Bio-Rad Laboratories, Hercules, CA). The antibodies used
were mouse monoclonal anti-RRM1 (1:500; Chemicon In-
ternational, Temecula, CA), antimouse IgG HPL whole
antibody (1:2000; Amersham Pharmacia Biotech, Little
Chalfont, UK), and anti--actin (Abcam Ltd., Cambridge,
UK). After adding the ECL blotting reagents (Amersham
Pharmacia Biotech), the membrane was exposed to high
performance autoradiography film (Amersham Pharmacia
Biotech).
Statistical Analysis
Clinical data analysis was performed using the SPSS 10.0
program (SPSS Inc., Chicago, IL). Time-dependent vari-
ables were estimated with a log-rank test using the Kaplan–
Meier method. We used the 2 test to correlate the SNPs
with toxicities. Allele or genotype frequency differences
between the patient and control populations were deter-
mined based on Hardy–Weinberg equilibrium using SNP
analyzer software (http://www.istech21.com/bionics/
consulting_6.htm). Haplotypes were constructed from ge-
Figure 1. Electropherograms of two nonsynonymous SNPs
and their flanking sequences in RRM1. Arrows indicate the
polymorphic and homozygous positions, and the homozygous
nucleotides are underlined.
Abbreviations: RRM1, ribonucleotide reductase M1
polypeptide; SNP, single-nucleotide polymorphism.
Table 2. Toxicity of chemotherapy by World Health Organization grade
Toxicity
World Health Organization grade
0 1 2 3 4
Number of patients (%)
Hematologic toxicity
Leukopenia 11 (14.9) 19 (25.7) 28 (37.8) 16 (21.6) 0 (0.0)
Neutropenia 14 (18.9) 15 (20.3) 21 (28.4) 22 (29.7) 2 (2.7)
Anemia 1 (1.4) 29 (39.2) 38 (51.4) 6 (8.1) 0 (0.0)
Thrombocytopenia 40 (54.1) 14 (18.9) 16 (21.6) 3 (4.1) 1 (1.4)
Nonhematologic toxicity
Diarrhea 21 (28.4) 44 (59.5) 9 (12.2) 0 (0.0) 0 (0.0)
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notype data using SNP analyzer software (http://www.
istech21.com/bionics/consulting_6.htm). The results were
considered significant when two-sided p-values were.05.
RESULTS
Patient Characteristics
Baseline characteristics for the 74 patients are shown in
Table 1. Among 71 evaluable patients, one complete re-
sponse (1.4%), 13 partial responses (18.3%), and 26 cases
of stable disease (36.6%) were documented. The overall re-
sponse rate was 19.7% and the disease control rate was
56.3%. The most common toxicity was neutropenia, and
32.4% of patients reported grade III–IV neutropenia. Only
5.5% of the patients showed grade III–IV thrombocyto-
penia. Nonhematologic toxicity was mild and only grade II
diarrhea was reported in 12.2% of the patients (Table 2).
Frequencies of SNPs
In breast cancer patients, the incidences of SNPs were 1.4%
in dCK (626 AG), 10.8% in DCTD (315 TC), 12.1% in
the first RRM1 (1082 CA), 40.5% in the second RRM1
(2455 AG), 44.6% in the third RRM1 (2464 GA), and
23.0% in the two RRM1 SNP sites (2455 AG and 2464
GA) (Fig. 1 and Table 3). In healthy volunteers, SNPs
were not found in dCK, and the incidences of SNPs were
7.1% in DCTD, 50.0% in the second RRM1, 64.3% in the
third RRM1, and 53.6% in the two RRM1 sites (2455 AG
and 2464 GA). When allele distributions of the three
genes were evaluated by the Hardy–Weinberg equation,
there were no differences in SNP frequencies between
healthy volunteers and breast cancer patients.
Association Between RRM1 SNP and Clinical
Phenotype
The associations between RRM1 SNP and treatment re-
sponse and toxicity were analyzed in breast cancer patients.
There were no differences in toxicity between patients
having any type of single SNP and patients having a wild-
type allele. However, in patients with double SNPs (2455
AG and 2464 GA) in RRM1, less toxicity, such as less
neutropenia (p .01), less leukopenia (p .004), a shorter
treatment delay (p .002), and a lower G-CSF requirement
(p .004) were observed when compared with wild-type or
single SNP patients (Fig. 2A–E). However, we could not
observe any significant association between SNP and tumor
response after gemcitabine monotherapy (data not shown).
Association Between RRM1 Haplotype and
Gemcitabine Toxicity
With three RRM1 SNPs, we constructed six haplotypes
(Table 4). A strong association was found between the
lower frequency of neutropenia and a haplotype containing
two SNPs (2455 AG and 2464 GA). No association was
observed between clinical response and RRM1 haplotype
(wild type, 26%; one SNP, 15%; double SNP, 18% re-
sponse rate) (Table 5). There was a tendency toward a poor
progression-free survival time in patients having the two
SNPs (2455 AG and 2464 GA) when compared with
wild-type or single SNP patients. In addition, poor overall
survival was found in patients having the two SNPs when
compared with wild-type or single SNP patients (Fig. 3).
The median times to progression of the patients with wild
type or single SNP and those with two SNPs were 17 and 12
weeks, respectively. The median overall survival times of















DCTD Exon 4 255 GC Ala/Ala 74 (100) 0 (0.0) 56 (100) 0 (0.0)
315 TC Val/Val 66 (89.1) 8 (10.8) 52 (92.5) 4 (7.1)
dCK Exon 4 626 AG Gln/Arg 73 (98.6) 1 (1.4) 56 (100) 0 (0.0)
Exon 5 753 AG Gln/Gln 74 (100) 0 (0.0) 56 (100) 0 (0.0)
RRM1 Exon 9 1082 CA Arg/Arg 65 (87.7) 9 (12.1) 28 (50.0) 28 (50.0)
Exon 19 2455 AG Thr/Thr 44 (59.5) 30 (40.5) 17 (30.4) 39 (69.6)
2464 GA Ala/Ala 41 (55.4) 33 (44.6) 20 (35.7) 36 (64.3)
2455 AG 2464 GA 57 (77.0) 17 (23.0) 26 (46.4) 30 (53.6)
Abbreviations: DCTD, deoxycytidine monophosphate deaminase; dCK, deoxycytidine kinase; RRM1, ribonucleotide
reductase M1 polypeptide; SNP, single-nucleotide polymorphism.
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the patients with wild type or single SNP and those with two
SNPs were 60 and 43 weeks, respectively.
In Vitro Association Between RRM1 SNP and
Chemosensitivity
We selected ten breast cancer cell lines to perform an asso-
ciation study between type of RRM1 SNP and in vitro cy-
totoxicity to gemcitabine. In breast cancer cell lines, as in
patients, RRM1 SNPs appeared more frequently than dCK
and DCTD SNPs. The incidences of SNPs were 50.0% in
the first RRM1 (1082 CA), 70.0% in the second RRM1
(2455 AG), 70.0% in the third RRM1 (2464 GA), and
60.0% in the two RRM1 SNP sites (2455 AG and 2464
GA).
Figure 2. Comparison of gemcitabine toxicity based on RRM1 SNPs. (A): Neutropenia. (B): Leukopenia. (C): Treatment delay.
(D): G-CSF requirement. (E): Comparison of leukopenia based on RRM1 haplotype.
Abbreviations: RRM1, ribonucleotide reductase M1 polypeptide; SNP, single-nucleotide polymorphism; wt, wild type.
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There were no differences in gemcitabine sensitivity be-
tween cell lines with single SNP and wild-type genotypes
(data not shown). Also, we observed that six cell lines with
two RRM1 SNPs (2455AG and 2464 GA) showed a
similar sensitivity to gemcitabine when compared with the
cell lines with wild type or one SNP (Fig. 4A). Cell lines
with RRM1 SNPs showed similar RNA and protein expres-
sion to those of wild-type cell lines (Fig. 4B).
DISCUSSION
Pharmacogenetics aims to identify genetic polymorphisms
that govern an individual’s response to specific drugs [15].
Clinical observation of an inherited difference in drug ef-
fect was first documented in the 1950s giving rise to the
field of pharmacogenetics later. One of the common varia-
tions in the human genome is SNP. More than 1.4 million
SNPs were identified in the initial sequencing of the human
genome, with over 60,000 of these in the coding region of
genes. Some of these SNPs have been shown to be associ-
ated with substantial changes in metabolism or in the effect
of anticancer agents, and some SNPs are now being applied
to predict clinical outcome [16–18].
In patients with double SNPs (2455 AG and 2464
GA) in RRM1, less toxicity was observed, suggesting an
association with treatment susceptibility. In contrast, we
could not observe any significant association between SNP
and tumor response. To date, few studies have addressed
the issue of the impact of SNP on chemotherapy efficacy.
The 5 tandem repeat polymorphism on the thymidylate
synthase gene has been identified as a predictor of clinical
outcome for 5-fluorouracil–based chemotherapy in colo-
rectal cancer and acute lymphoblastic leukemia [19]. Be-
cause a double SNP was found to be associated with
gemcitabine toxicity, we aimed to assess the potential role
of specific haplotypes in influencing gemcitabine suscepti-
bility. A strong association was observed between neutro-
penia and the RRM1 haplotype containing two SNPs (2455
AG and 2464 GA). No association was observed be-
tween clinical response and RRM1 haplotype, but there was
a tendency toward poor progressive-free survival in pa-
tients having the haplotype with double SNPs when com-
pared with wild-type or single SNP patients. We suggest
that patients with the RRM1 haplotype 2455 AG and 2464
GA are genetically more resistant to gemcitabine (rela-
tively poor progression-free survival) and less susceptible
to gemcitabine (less general toxicity) than wild-type or
single SNP RRM1 patients.
It is difficult to draw a definite conclusion from an as-
sociation study between the SNPs of genomic DNA and
clinical phenotypes. Our hypothesis was that patients with
sequence variations might show different responses or
toxicities from those of patients with wild-type alleles. A
silent mutation that does not change the amino acid se-
quence can alter protein function. In contrast, a wobble
protein, as in our cases, can show differences in clinical
phenotypes. The selected SNP sites in our study are located
at the end of mRNA and they might be implicated in nucle-
otide transport or metabolism. Alternatively, the anticodon
or other molecules may be indirectly influenced during
transcription or translation. Similarly, the molecular mech-
anisms of transcription enhancement by tandem repeats in
the excision-repair cross-complementing 1 gene remain
largely unknown [19].






H1 C A G 26 (35.1) 2 (20.0)
H2 C A A 14 (18.9) 1 (10.0)
C G G 10 (13.5) 1 (10.0)
A A G 3 (4.1) 0 (0.0)
H3 C G A 16 (21.6) 1 (10.0)
A G A 2 (2.7) 5 (50.0)
A G G 3 (4.1) 0 (0.0)
Total 74 10
H1, wild type; H2, single SNP site (1082 CA, 2455
AG, 2464 GA); H3, double SNP (2455 AG and
2464 GA).
Abbreviation: SNP, single-nucleotide polymorphism.
Table 5. Comparison of tumor response based on RRM1 haplotype
Haplotype CR/PR (%) SD (%) PD (%)
Total
(n 71)
Wild type H1 6 (26.0) 9 (39.0) 8 (35.0) 23
1 SNP H2 4 (15.0) 9 (35.0) 13 (50.0) 26
2/3 SNP H3 4 (18.0) 8 (36.0) 10 (45.0) 22
Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; SNP, single-
nucleotide polymorphism.
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RR is usually overexpressed in cancer cells, and there-
fore RR inhibitors might be useful as anticancer drugs, like
gemcitabine [20]. It has been reported that the increase in
mRNA level of RRM1 results in drug resistance [12]. With
nonsynonymous SNP sites in RRM1 gene, we found similar
chemosensitivity, mRNA, and protein level as with the
wild type. In contrast, breast cancer patients having double
SNPs (2455 AG and 2464 GA) showed resistance to
gemcitabine. Possible explanations for this gap between the
in vitro and in vivo results are: first, double SNPs can cause
a different phenotype than the single SNP in RRM1 during
chronic exposure to chemotherapy in patients, and second,
with two SNPs, a difference in the three-dimensional struc-
ture might be induced in patients without any change at the
Figure 3. Comparison of survival according to RRM1 haplo-
type. (A): Progression-free survival. (B): Overall survival. H1,
wild-type allele; H2, single SNP; H3, double SNP.
Abbreviations: RRM1, ribonucleotide reductase M1
polypeptide; SNP, single-nucleotide polymorphism.
Figure 4. In vitro study of RRM1 SNP and chemosensitivity.
(A): Chemosensitivity (IC50) of ten breast cancer cell lines.
(B): Expression levels of RRM1 in cancer cell lines. *Single
SNP, **double SNP.
Abbreviations: IC50, 50% inhibitory concentration;
RRM1, ribonucleotide reductase M1 polypeptide; SNP, sin-
gle-nucleotide polymorphism.
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transcription and translation level of RR. One retrospective
study indicated that RRM1 levels might influence both the
response and survival of non-small cell lung cancer patients
to gemcitabine–cisplatin combination therapy [21]. RRM1
is suggested to act as a “molecular sink” for gemcitabine,
whereby the drug binds irreversibly to subunit RRM1 and
inactivates it. Therefore, our hypothesis is that the altered
sequence of RRM1 might induce a structural change in
RRM1 that could easily bind to gemcitabine and thus in-
duce drug resistance. Under this hypothesis, we chose
cSNP in a nonsynonymous form located within the func-
tional and conserved region of the gene. For the confirma-
tion of this hypothesis, an RRM1 simulation study with a
three-dimensional structure and biochemical binding assay
to gemcitabine is required in the future. Also, further mo-
lecular study is needed for understanding the mechanism of
gemcitabine resistance with double SNPs of RRM1.
Although we cannot definitely predict drug toxicity or
efficacy with the cSNPs of RRM1, the haplotype with dou-
ble SNPs (2455 AG and 2464 GA) showed a high as-
sociation with gemcitabine susceptibility, suggesting this
haplotype as a potential association marker for gemcitabine
compliance. A prospective comparison study using RRM1
SNP as a biomarker for gemcitabine toxicity, using it as a
randomization factor, is warranted in the future. With this
prospective confirmation, RRM1 SNP can be used as a
biomarker for the prediction of toxicity or prognosis.
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